865.409.9760
Weight loss program with
semaglutide & tirzepatide
If you struggle with obesity or your weight negatively impacts your health and enjoyment of life, our Team understands the difficulties you may be experiencing. That’s why we take a personalized approach to medical weight management and weight loss while taking into consideration the uniqueness of each individual client.
Your Weight Loss is a Journey
Our weight loss program is here to help you be successful in that journey. This program is designed to help you maximize your transformation goals! We want your focus to be on improved health and not just the number on the scale. If you’re looking for a positive change, find out if our program is right for you. You’re one step closer to changing your life forever!
How your journey begins:
-
A personalized consultation with our Nurse Practitioner designed to fit your needs
-
In-depth Medical History and Review
-
Lab Work
-
InBody Scan
-
Physical Activity and Nutritional Guidance
-
Follow-up Analysis
-
Maintenance objectives and goals for long-term lifestyle changes
Semaglutide:
Semaglutide is a Glucagon-like peptide (GLP-1) agonist in which the FDA has approved for chronic weight management. The medicine mimics a hormone that is already released in the small intestine. In other words, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance.
Tirzepatide:
Like Semaglutide, the US Food and Drug Administration recently approved subcutaneous Tirzepatide, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, for chronic weight management. Given this medication has two incretins (or naturally occurring peptide hormones that are released in the small intestine) it can be more effective with weight loss and lowering blood sugar when compared to other GLP-1 medications.
Both of these medications help with weight loss by:
-
Delaying gastric emptying and slowing intestinal motility. This results in satiety (or feeling full).
-
Lowering blood glucose in the bloodstream by stimulating insulin secretion from the pancreas and decreasing the glucose produced in the liver.
-
Sends signals to the hypothalamus, the brain’s appetite controller, to tell the body to feel full and eat less.
The FDA has approved this, in combination with diet and lifestyle modifications, for those who are obese or for people who are overweight along with other health conditions if losing weight can help manage the coexisting conditions.
There are side effects with these medications, and they may not be right for everyone. You are not a good candidate for these medications if you have any of the following: diabetic retinopathy, low blood sugar, decreased kidney function, pancreatitis, or gallbladder disease. You are also not a candidate if you or a family member has ever been diagnosed with medullary thyroid carcinoma or any other thyroid cancers.
Dungan, K., DeSantis, A.,(2024).Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. UpToDate. https://www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus